01 MAY 2018

UDG Healthcare plc ("the Group"), a leading international healthcare services provider, will issue its interim results for the half year ended 31 March 2018 at 07:00am (BST) on Tuesday 22 May 2018.

Management will be hosting a presentation for analysts and investors at the London Stock Exchange at 08:30am (BST) to discuss the company's half year results and provide an update on each of the Group's divisions.

Analysts and investors wishing to attend are asked to contact Powerscourt on the details below, as all attendees need to be pre-registered. The presentation will also be available via live audio webcast and conference call, the details of which are below.

Audio webcast:


Conference call dial-in details:



+44 (0)330 336 9105


+353 (0)1 246 5638

United States of America

+1 929-477-0448

Participant Code



For further information, please contact:

UDG Healthcare plc

Keith Byrne

Head of Investor Relations, Strategy & Corporate Communications

Tel: +353-1-468-9000


Lisa Kavanagh / Isabelle Saber / Sam Austrums

Tel: +44-207-250-1446



About UDG Healthcare plc:

UDG Healthcare plc (LON: UDG) is a leading international partner of choice delivering advisory, communication, commercial, clinical and packaging services to the healthcare industry, employing 9,000 people with operations in 24 countries and delivering services in over 50 countries.

UDG Healthcare plc operates across three divisions: Ashfield, Sharp and Aquilant.

Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across three areas of activity: advisory, communication, commercial & clinical services. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle. Ashfield provides field and contact centre sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services to over 300 healthcare companies.

Sharp is a global leader in contract commercial packaging and clinical trial supply chain solutions services for the pharmaceutical and biotechnology industries, operating from state-of-the-art facilities in the US and Europe.

Aquilant is leading distributor of specialist medical and scientific products, providing outsourced sales, marketing, distribution and engineering services to the medical and scientific sectors in the UK, Ireland and the Netherlands.

The company is listed on the London Stock Exchange and is a constituent of the FTSE 250.

For more information, please go to: www.udghealthcare.com